Insider Buying: TriSalus Life Sciences (NASDAQ:TLSI) Director Acquires 60,000 Shares of Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Director Mats Wahlstrom acquired 60,000 shares of TriSalus Life Sciences stock in a transaction dated Friday, May 15th. The stock was bought at an average price of $2.53 per share, with a total value of $151,800.00. Following the completion of the purchase, the director directly owned 147,555 shares in the company, valued at $373,314.15. This represents a 68.53% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website.

TriSalus Life Sciences Stock Performance

Shares of NASDAQ:TLSI traded up $0.35 during midday trading on Monday, hitting $3.03. The company had a trading volume of 773,435 shares, compared to its average volume of 276,402. The company has a debt-to-equity ratio of 2.58, a current ratio of 5.78 and a quick ratio of 5.46. The company has a market cap of $185.77 million, a price-to-earnings ratio of -2.15 and a beta of 0.56. TriSalus Life Sciences, Inc. has a 12-month low of $2.20 and a 12-month high of $7.95. The company has a fifty day moving average of $4.18 and a two-hundred day moving average of $5.13.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its quarterly earnings data on Thursday, March 5th. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.01. The company had revenue of $13.21 million during the quarter, compared to analysts’ expectations of $13.20 million. On average, equities research analysts expect that TriSalus Life Sciences, Inc. will post -0.45 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. First Light Asset Management LLC bought a new position in shares of TriSalus Life Sciences during the 1st quarter valued at about $20,267,000. Nantahala Capital Management LLC boosted its holdings in shares of TriSalus Life Sciences by 1.5% during the 4th quarter. Nantahala Capital Management LLC now owns 2,070,827 shares of the company’s stock valued at $14,454,000 after purchasing an additional 30,582 shares during the last quarter. Wasatch Advisors LP bought a new position in shares of TriSalus Life Sciences during the 1st quarter valued at about $5,752,000. Vanguard Group Inc. boosted its holdings in shares of TriSalus Life Sciences by 42.4% during the 3rd quarter. Vanguard Group Inc. now owns 1,159,575 shares of the company’s stock valued at $5,392,000 after purchasing an additional 345,186 shares during the last quarter. Finally, Gilder Gagnon Howe & Co. LLC boosted its holdings in shares of TriSalus Life Sciences by 32.1% during the 2nd quarter. Gilder Gagnon Howe & Co. LLC now owns 1,092,975 shares of the company’s stock valued at $5,957,000 after purchasing an additional 265,618 shares during the last quarter. Institutional investors own 2.58% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Wall Street Zen raised shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a report on Saturday, March 7th. Canaccord Genuity Group dropped their target price on shares of TriSalus Life Sciences from $12.00 to $7.00 and set a “buy” rating for the company in a report on Friday, March 6th. Weiss Ratings downgraded shares of TriSalus Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday. Finally, Lake Street Capital dropped their target price on shares of TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, May 13th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $7.50.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.